Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Aflibercept
Drug ID BADD_D00048
Description Aflibercept is a recombinant protein composed of the binding domains of two human vascular endothelial growth factor (VEGF) receptors fused with the Fc region of human immunoglobulin gamma 1 (IgG1). Structurally, Aflibercept is a dimeric glycoprotein with a protein molecular weight of 96.9 kilo Daltons (kDa). It contains approximately 15% glycosylation to give a total molecular weight of 115 kDa. All five putative N-glycosylation sites on each polypeptide chain predicted by the primary sequence can be occupied with carbohydrate and exhibit some degree of chain heterogeneity, including heterogeneity in terminal sialic acid residues, except at the single unsialylated site associated with the Fc domain. Aflibercept, as an ophthalmic agent, is used in the treatment of macular edema following Central Retinal Vein Occlusion (CRVO) and neovascular Age-Related Macular Degeneration (AMD). Ziv-aflibercept, under the brand name Zaltrap, was developed as an injection for treatment of metastatic colorectal cancer. FDA approved in November 18, 2011 and EMA approved in November 2012.
Indications and Usage The opthalmic agent is used for the treatment of neovascular (wet) age-related mascular degeneration (AMD) and macular edema following central retinal vein occulsion (CRVO). The systemic injection, known as ziv-aflibercept, in combination with 5-fluorouracil, leucovorin, irinotecan-(FOLFIRI), is for the treatment of metastatic colorectal cancer that is resistant to or progressed following treatment with oxaliplatin.
Marketing Status Prescription
ATC Code L01XX44; S01LA05
DrugBank ID DB08885
KEGG ID D09574
MeSH ID C533178
PubChem ID Not Available
NDC Product Code 61434-007; 61755-005
Synonyms aflibercept | VEGF Trap - regeneron | VEGF Trap-Eye | VEGF-Trap | eylea | Zaltrap | AVE 0005 | AVE0005 | AVE-0005 | AVE 005 | AVE005 | AVE-005 | ZIV-aflibercept
Chemical Information
Molecular Formula Not Available
CAS Registry Number 862111-32-8
SMILES Not Available
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal pain07.01.05.002--
Abdominal pain upper07.01.05.003--
Alanine aminotransferase increased13.03.01.003--
Anaphylactic reaction24.06.03.006;
Anaphylactoid reaction24.06.03.007; Available
Aspartate aminotransferase increased13.03.01.006--
Asthenia08.01.01.001--Not Available
Blood creatinine increased13.13.01.004--
Conjunctival haemorrhage24.07.05.001; Available
Corneal epithelium defect06.06.03.012--Not Available
Corneal erosion06.06.03.003--Not Available
Corneal oedema06.04.02.001--Not Available
Eye inflammation06.04.05.002--Not Available
Eye pain06.08.03.002--
Eyelid oedema23.04.01.003;; Available
Injection site haemorrhage24.07.01.010;; Available
Injection site pain12.07.03.011; Available
Intraocular pressure increased13.07.04.002--Not Available
The 1th Page    1 2    Next   Last    Total 2 Pages